Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

NCT05265650 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG: BO-112 in combination with ablative radiotherapy (SABR) and nivolumab
PROCEDURE: Tissue Biopsies

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Collaborators

[object Object]